Beta-blocker use in severe sepsis and septic shock: a systematic review

References

• Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011;123:2434-506
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254-62
   PubMed Web of Science ®Google Scholar
• Sanfilippo F, Santonocito C, Foex P. Use of beta-blockers in non-cardiac surgery: an open debate. Minerva Anestesiologica 2014;80:482-94
   PubMed Web of Science ®Google Scholar
• Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:77-137
   PubMed Web of Science ®Google Scholar
• Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014;35:2383-431
   PubMed Web of Science ®Google Scholar
• Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006;34:344-53
   PubMed Web of Science ®Google Scholar
• Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 2013;310:1683-91
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical Research Ed) 2009;339:b2700
   PubMed Web of Science ®Google Scholar
• Sanfilippo F, Santonocito C, Maybauer MO. Short-acting beta-blocker administration in patients with septic shock. JAMA 2014;311:736
   PubMed Web of Science ®Google Scholar
• Yang S, Liu Z, Yang W, et al. [Effects of the beta-blockers on cardiac protection and hemodynamics in patients with septic shock: a prospective study]. Zhonghua wei zhong bing ji jiu yi xue 2014;26:714-17
   PubMedGoogle Scholar
• Morelli A, Donati A, Ertmer C, et al. Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. Crit Care Med 2013;41:2162-8
   PubMed Web of Science ®Google Scholar
• Balik M, Rulisek J, Leden P, et al. Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. Wiener Klinische Wochenschrift 2012;124:552-6
   PubMed Web of Science ®Google Scholar
• Morelli A, D'Egidio A, Orecchioni A, et al. Heart rate reduction with esmolol in septic shock: effects on myocardial performance. Crit Care 2014;18(Suppl 1):P162
   Google Scholar
• Schmittinger CA, Dunser MW, Haller M, et al. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care (London, England) 2008;12:R99
   PubMed Web of Science ®Google Scholar
• Gutierrez J, Hossam A, Lazarezcu R, et al. Effect of beta blockers on sepsis outcome. Med Sci Mon Int Med J Exp Clin Res 2009;15:CR499-503
   Google Scholar
• Berk JL, Hagen JF, Maly G, Koo R. The treatment of shock with beta adrenergic blockade. Arch Surg (Chicago, Ill 1960) 1972;104:46-51
   PubMed Web of Science ®Google Scholar
• Berk JL, Hagen JF, Dunn JM. The role of beta adrenergic blockade in the treatment of septic shock. Surg Gynecol Obstet 1970;130:1025-34
   PubMedGoogle Scholar
• Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis. Surgery 2006;139:686-94
   PubMed Web of Science ®Google Scholar
• Sander O, Welters ID, Foex P, Sear JW. Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications. Crit Care Med 2005;33:81-8; discussion 241-2
   PubMed Web of Science ®Google Scholar
• Vellinga NA, Boerma EC, Koopmans M, et al. International study on microcirculatory shock occurrence in acutely ill patients. Crit Care Med 2015;43:48-56
   PubMed Web of Science ®Google Scholar
• Mori K, Morisaki H, Yajima S, et al. Beta-1 blocker improves survival of septic rats through preservation of gut barrier function. Intensive Care Med 2011;37:1849-56
   PubMed Web of Science ®Google Scholar
• Ibrahim-Zada I, Rhee P, Gomez CT, et al. Inhibition of sepsis-induced inflammatory response by beta1-adrenergic antagonists. J Trauma Acute Care Surg 2014;76:320-8
   PubMed Web of Science ®Google Scholar
• Ackland GL, Yao ST, Rudiger A, et al. Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1-adrenoceptor blockade in severe sepsis in rats. Crit Care Med 2010;38:388-94
   PubMed Web of Science ®Google Scholar
• Macchia A, Romero M, Comignani PD, et al. Previous prescription of beta-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis. Crit Care Med 2012;40:2768-72
   PubMed Web of Science ®Google Scholar
• Christensen S, Johansen MB, Tonnesen E, et al. Preadmission beta-blocker use and 30-day mortality among patients in intensive care: a cohort study. Crit Care (London, England) 2011;15:R87
   PubMed Web of Science ®Google Scholar
• Nuding S, Ebelt H, Hoke RS, et al. Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine: MODI (f)Y trial. Clin Res Cardiol 2011;100:915-23
   PubMed Web of Science ®Google Scholar
• Furian T, Aguiar C, Prado K, et al. Ventricular dysfunction and dilation in severe sepsis and septic shock: relation to endothelial function and mortality. J Crit Care 2012;27:319 e9-15
   PubMed Web of Science ®Google Scholar
• Brown SM, Pittman JE, Hirshberg EL, et al. Diastolic dysfunction and mortality in early severe sepsis and septic shock: a prospective, observational echocardiography study. Crit Ultrasound J 2012;4:8
   PubMedGoogle Scholar
• Landesberg G, Gilon D, Meroz Y, et al. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J 2012;33:895-903
   PubMed Web of Science ®Google Scholar
• Pulido JN, Afessa B, Masaki M, et al. Clinical spectrum, frequency, and significance of myocardial dysfunction in severe sepsis and septic shock. Mayo Clin Proc 2012;87:620-8
   PubMed Web of Science ®Google Scholar
• Huang SJ, Nalos M, McLean AS. Is early ventricular dysfunction or dilatation associated with lower mortality rate in adult severe sepsis and septic shock? A meta-analysis. Crit Care (London, England) 2013;17:R96
   PubMed Web of Science ®Google Scholar
• Sanfilippo F, Corredor C, Fletcher N, et al. Erratum to: Diastolic dysfunction and mortality in septic patients: a systematic review and meta-analysis. Intensive Care Med 2015;41:1178-9
   PubMed Web of Science ®Google Scholar
• Sanfilippo F, Corredor C, Fletcher N, et al. Diastolic dysfunction and mortality in septic patients: a systematic review and meta-analysis. Intensive Care Med 2015;41:1004-13
   PubMed Web of Science ®Google Scholar
• Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004;6:453-61
   PubMed Web of Science ®Google Scholar
• Wang JF, Meissner A, Malek S, et al. Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis. Am J Physiol Heart Circ Physiol 2005;289:H1577-83
   PubMed Web of Science ®Google Scholar
• Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005;352:539-48
   PubMed Web of Science ®Google Scholar
• O'Dwyer MJ, Mankan AK, Stordeur P, et al. The occurrence of severe sepsis and septic shock are related to distinct patterns of cytokine gene expression. Shock (Augusta, Ga) 2006;26:544-50
   PubMed Web of Science ®Google Scholar
• Cavaillon JM, Adib-Conquy M, Fitting C, et al. Cytokine cascade in sepsis. Scand J Infect Dis 2003;35:535-44
   PubMed Web of Science ®Google Scholar
• Gullo A, Foti A, Murabito P, et al. Spectrum of sepsis, mediators, source control and management of bundles. Front Biosci (Elite edition) 2010;2:906-11
   PubMedGoogle Scholar
• Cain BS, Meldrum DR, Dinarello CA, et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 1999;27:1309-18
   PubMed Web of Science ®Google Scholar
• Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol 2003;92:3-9J
   PubMed Web of Science ®Google Scholar
• de Montmollin E, Aboab J, Mansart A, Annane D. Bench-to-bedside review: beta-adrenergic modulation in sepsis. Crit Care (London, England) 2009;13:230
   PubMed Web of Science ®Google Scholar
• Suzuki T, Morisaki H, Serita R, et al. Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 2005;33:2294-301
   PubMed Web of Science ®Google Scholar
• Hagiwara S, Iwasaka H, Maeda H, Noguchi T. Landiolol, an ultrashort-acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model. Shock (Augusta, Ga) 2009;31:515-20
   PubMed Web of Science ®Google Scholar
• Calzavacca P, Lankadeva YR, Bailey SR, et al. Effects of selective ss1-adrenoceptor blockade on cardiovascular and renal function and circulating cytokines in ovine hyperdynamic sepsis. Crit Care (London, England) 2014;18:610
   PubMed Web of Science ®Google Scholar
• Lang CH, Nystrom G, Frost RA. Beta-adrenergic blockade exacerbates sepsis-induced changes in tumor necrosis factor alpha and interleukin-6 in skeletal muscle and is associated with impaired translation initiation. J Trauma 2008;64:477-86
   PubMed Web of Science ®Google Scholar
• Oberbeck R, Schmitz D, Wilsenack K, et al. Adrenergic modulation of survival and cellular immune functions during polymicrobial sepsis. Neuroimmunomodulation 2004;11:214-23
   PubMed Web of Science ®Google Scholar
• Schmitz D, Wilsenack K, Lendemanns S, et al. beta-Adrenergic blockade during systemic inflammation: impact on cellular immune functions and survival in a murine model of sepsis. Resuscitation 2007;72:286-94
   PubMed Web of Science ®Google Scholar
• Giebelen IA, Leendertse M, Dessing MC, et al. Endogenous beta-adrenergic receptors inhibit lipopolysaccharide-induced pulmonary cytokine release and coagulation. Am J Respir Cell Mol Biol 2008;39:373-9
   PubMed Web of Science ®Google Scholar
• Muthu K, He LK, Szilagyi A, et al. Propranolol restores the tumor necrosis factor-alpha response of circulating inflammatory monocytes and granulocytes after burn injury and sepsis. J Burn Care Res 2009;30:8-18
   PubMed Web of Science ®Google Scholar
• Muthu K, Deng J, Gamelli R, et al. Adrenergic modulation of cytokine release in bone marrow progenitor-derived macrophage following polymicrobial sepsis. J Neuroimmunol 2005;158:50-7
   PubMed Web of Science ®Google Scholar
• Deng J, Muthu K, Gamelli R, et al. Adrenergic modulation of splenic macrophage cytokine release in polymicrobial sepsis. Am J Physiol Cell Physiol 2004;287:C730-6
   Google Scholar
• Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013;110:3507-12
   PubMed Web of Science ®Google Scholar
• Plank LD, Connolly AB, Hill GL. Sequential changes in the metabolic response in severely septic patients during the first 23 days after the onset of peritonitis. Ann Surg 1998;228:146-58
   PubMed Web of Science ®Google Scholar
• Trager K, DeBacker D, Radermacher P. Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care 2003;9:271-8
   PubMedGoogle Scholar
• Lang CH. Sepsis-induced insulin resistance in rats is mediated by a beta-adrenergic mechanism. Am J Physiol 1992;263(4 Pt 1):E703-11
   Google Scholar
• Chu CA, Sindelar DK, Igawa K, et al. The direct effects of catecholamines on hepatic glucose production occur via alpha(1)- and beta(2)-receptors in the dog. Am J Physiol Endocrinol Metabol 2000;279:E463-73
   Google Scholar
• Tappy L, Chiolero R. Substrate utilization in sepsis and multiple organ failure. Crit Care Med 2007;35(9 Suppl):S531-4
   Google Scholar
• Levy B, Desebbe O, Montemont C, Gibot S. Increased aerobic glycolysis through beta2 stimulation is a common mechanism involved in lactate formation during shock states. Shock (Augusta, Ga) 2008;30:417-21
   PubMed Web of Science ®Google Scholar
• Jeschke MG, Norbury WB, Finnerty CC, et al. Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children. J Trauma 2007;62:676-81
   PubMed Web of Science ®Google Scholar
• Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukocyte Biol 2008;83:536-45
   PubMed Web of Science ®Google Scholar
• von Kanel R, Dimsdale JE, Adler KA, et al. Effects of nonspecific beta-adrenergic stimulation and blockade on blood coagulation in hypertension. J Applied Physiol (Bethesda, Md: 1985) 2003;94:1455-9
   PubMed Web of Science ®Google Scholar
• Boman K, Boman JH, Andersson J, et al. Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. Clin Appl Thromb Hemost 2010;16:146-52
   PubMed Web of Science ®Google Scholar
• Markel A, Brook JG, Levy Y, et al. Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol. Br J Clin Pharmacol 1983;16:663-8
   PubMed Web of Science ®Google Scholar
• Horn EH, Jalihal S, Bruce M, et al. The effect on platelet behaviour of treatment with atenolol and the combination of atenolol and nifedipine in healthy volunteers. Platelets 1992;3:15-21
   PubMedGoogle Scholar
• Gleerup G, Mehlsen J, Winther K. Does calcium channel blockade and beta-adrenergic blockade affect platelet function and fibrinolysis to a varying degree? J Cardiovasc Pharmacol 1995;25:87-9
   PubMed Web of Science ®Google Scholar